NZ575550A - Rifaximin - Google Patents

Rifaximin

Info

Publication number
NZ575550A
NZ575550A NZ575550A NZ57555007A NZ575550A NZ 575550 A NZ575550 A NZ 575550A NZ 575550 A NZ575550 A NZ 575550A NZ 57555007 A NZ57555007 A NZ 57555007A NZ 575550 A NZ575550 A NZ 575550A
Authority
NZ
New Zealand
Prior art keywords
rifaximin
water
amorphous
solvent
solid
Prior art date
Application number
NZ575550A
Other languages
English (en)
Inventor
Rajendra Narayanrao Kankan
Manjinder Singh Phull
Dharmaraj Ramachandra Rao
Maruti Ghagare
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38815026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ575550(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of NZ575550A publication Critical patent/NZ575550A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ575550A 2006-09-22 2007-09-24 Rifaximin NZ575550A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1520MU2006 2006-09-22
PCT/GB2007/003629 WO2008035109A1 (en) 2006-09-22 2007-09-24 Rifaximin

Publications (1)

Publication Number Publication Date
NZ575550A true NZ575550A (en) 2011-12-22

Family

ID=38815026

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ575550A NZ575550A (en) 2006-09-22 2007-09-24 Rifaximin

Country Status (8)

Country Link
US (8) US8633234B2 (https=)
EP (1) EP2069363B1 (https=)
JP (7) JP2010504314A (https=)
KR (2) KR101667534B1 (https=)
AU (1) AU2007298733B2 (https=)
CA (1) CA2663776C (https=)
NZ (1) NZ575550A (https=)
WO (1) WO2008035109A1 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
KR101667534B1 (ko) * 2006-09-22 2016-10-19 씨아이피엘에이 엘티디. 리팍시민
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
UA113275C2 (xx) 2008-02-25 2017-01-10 ζ-ФОРМА РИФАКСИМІНУ І ЇЇ ЗАСТОСУВАННЯ
HUE048293T2 (hu) 2008-10-02 2020-07-28 Salix Pharmaceuticals Ltd Eljárások hepatikus enkefalopátia kezelésére
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
ES2718614T3 (es) 2008-12-10 2019-07-03 Cipla Ltd Complejos de rifaximina
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
WO2011080691A1 (en) * 2009-12-28 2011-07-07 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
IT1399141B1 (it) * 2010-04-02 2013-04-05 Secci Metodo per la preparazione di rifaximina in stato amorfo.
IT1398550B1 (it) * 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
AU2011225810B2 (en) 2010-03-10 2014-11-06 Lupin Limited Rifaximin ready-to-use suspension
CA2802874A1 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
WO2012035544A2 (en) * 2010-09-13 2012-03-22 Sequent Scientific Ltd. A novel polymorphic form of rifaximin and process for its preparation
WO2012060675A1 (es) * 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
SG192122A1 (en) * 2011-02-11 2013-08-30 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof
WO2012150561A1 (en) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITMI20110983A1 (it) * 2011-05-30 2012-12-01 A M S A Anonima Materie Sint & Affini S P A Amorfo di rifaximina e processo per la sua preparazione
WO2013027227A1 (en) * 2011-07-20 2013-02-28 Ind-Swift Laboratories Limited Novel polymorphic form i of rifaximin
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
CA2854380A1 (en) * 2011-11-02 2013-05-10 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs) and infections
CA2876737A1 (en) 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014140995A2 (en) 2013-03-15 2014-09-18 Alfa Wassermann S.P.A. Method for diagnosing vaginal infections
CN105142636A (zh) 2013-03-15 2015-12-09 意大利阿尔法韦士曼制药公司 用于治疗阴道感染的利福昔明
EP2983647B1 (en) 2013-04-12 2020-09-09 Alfasigma S.p.A. Nsaid administration and related compositions, methods and systems
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
EP3134415A4 (en) * 2014-04-19 2017-10-25 Granules India Limited An improved process for the preparation of rifamycin derivatives
US10685402B1 (en) 2014-04-25 2020-06-16 State Farm Mutual Automobile Insurance Company Systems and methods for homeowner-directed risk of property damage mitigation
NZ723571A (en) 2014-05-12 2020-02-28 Alfasigma Spa New solvated crystal form of rifaximin, production, compositions and uses thereof
MX381919B (es) * 2014-06-30 2025-03-13 Salix Pharmaceuticals Inc Métodos para repetir tratamiento de síndrome del intestino irritable (ibs).
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
US10353359B1 (en) 2014-10-07 2019-07-16 State Farm Mutual Automobile Insurance Company Systems and methods for managing smart devices based upon electrical usage data
WO2016063289A2 (en) * 2014-10-22 2016-04-28 Strides Arcolab Limited Pharmaceutical tablet compositions comprising rifaximin
US9988398B2 (en) 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
WO2018178777A1 (en) * 2017-03-31 2018-10-04 Granules India Limited Process for the preparation of rifaximin crystalline form
CN111423456A (zh) * 2020-04-03 2020-07-17 南京昊绿生物科技有限公司 一种利福昔明-d6的合成工艺
WO2021229480A1 (en) * 2020-05-15 2021-11-18 Atra Pharmaceuticals Limited Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin
CN117447487A (zh) * 2022-07-19 2024-01-26 重庆圣华曦药业股份有限公司 一种利福昔明的纯化方法及其在利福昔明片剂中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3089818A (en) 1960-06-02 1963-05-14 Baxter Laboratories Inc Water dispersible antibiotics
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1294205B1 (it) 1997-07-23 1999-03-24 Farmigea Spa Procedimento per la solubilizzazione in acqua e in veicoli acquosi di sostanze farmacologicamente attive
JPH11246404A (ja) * 1998-03-04 1999-09-14 Taiho Yakuhin Kogyo Kk 吸収を改善した医薬組成物
WO2001051919A2 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
WO2002032459A2 (en) 2000-10-17 2002-04-25 Massachusetts Institute Of Technology Method of increasing the efficacy of antibiotics by complexing with cyclodextrins
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
AU2005297923B2 (en) * 2004-10-25 2010-12-23 Japan Tobacco Inc. Solid medicinal preparation improved in solubility and stability and process for producing the same
PT1698630E (pt) * 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
US20070082870A1 (en) 2005-10-11 2007-04-12 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
KR101667534B1 (ko) * 2006-09-22 2016-10-19 씨아이피엘에이 엘티디. 리팍시민
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
WO2009137672A1 (en) 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
ES2718614T3 (es) 2008-12-10 2019-07-03 Cipla Ltd Complejos de rifaximina

Also Published As

Publication number Publication date
AU2007298733B2 (en) 2012-11-08
US12109200B2 (en) 2024-10-08
KR101667534B1 (ko) 2016-10-19
CA2663776A1 (en) 2008-03-27
US20230116935A1 (en) 2023-04-20
JP2022003052A (ja) 2022-01-11
JP2018127470A (ja) 2018-08-16
KR20090080048A (ko) 2009-07-23
KR101480732B1 (ko) 2015-01-21
US20180235944A1 (en) 2018-08-23
US20200368212A1 (en) 2020-11-26
CA2663776C (en) 2016-01-26
US10702505B2 (en) 2020-07-07
JP2016065058A (ja) 2016-04-28
JP2020128380A (ja) 2020-08-27
US9877953B2 (en) 2018-01-30
JP2022003038A (ja) 2022-01-11
EP2069363B1 (en) 2013-03-20
JP2010504314A (ja) 2010-02-12
US8633234B2 (en) 2014-01-21
EP2069363A1 (en) 2009-06-17
KR20140131543A (ko) 2014-11-13
US20160374999A1 (en) 2016-12-29
WO2008035109A1 (en) 2008-03-27
US20150266898A1 (en) 2015-09-24
JP7346353B2 (ja) 2023-09-19
US20140128419A1 (en) 2014-05-08
US20120116071A1 (en) 2012-05-10
US20090312357A1 (en) 2009-12-17
US9403844B2 (en) 2016-08-02
JP2023078160A (ja) 2023-06-06
AU2007298733A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
US12109200B2 (en) Rifaximin
US8853231B2 (en) Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
EP1601680B1 (en) Methods of making ferric organic compounds
KR100855084B1 (ko) 리팍시민의 다형체, 그의 제조방법, 및 그의의약품으로서의 용도
EP2773620B1 (en) Ivabradine hydrochloride form iv
CN1900077A (zh) 利福昔明的新多晶型形式,它们的制备方法及其在药物制剂中的用途
CA2844765C (en) Polymorph of rifaximin and process for the preparation thereof
IL175512A (en) A pure crystalline form of aripiprazole
JP5642766B2 (ja) アデフォビルジピボキシルの新規結晶形及びその製造方法
HK1077580B (en) Methods of making ferric organic compounds

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 24 SEP 2017 BY CPA GLOBAL

Effective date: 20140822

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 SEP 2018 BY THOMSON REUTERS

Effective date: 20170819

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 SEP 2019 BY THOMSON REUTERS

Effective date: 20180816

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 SEP 2020 BY THOMSON REUTERS

Effective date: 20190817

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 SEP 2021 BY THOMSON REUTERS

Effective date: 20200820

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 SEP 2022 BY ANAQUA SERVICES

Effective date: 20210819

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 SEP 2023 BY ANAQUA SERVICES

Effective date: 20220819

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 SEP 2024 BY ANAQUA SERVICES

Effective date: 20230823

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 SEP 2025 BY ANAQUA SERVICES

Effective date: 20240820

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 SEP 2026 BY ANAQUA SERVICES

Effective date: 20250820